Search

Search Constraints

You searched for: Author/Creator Miyake, Kentaro

Search Results

11. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. (June 2018)

12. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility complex class I‐related chain A/B expression. Issue 3 (12th June 2017)

13. Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model. (1st June 2019)

14. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. (28th September 2018)

15. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. (1st November 2020)

16. Outcomes of neoadjuvant gemcitabine plus S‐1 and radiation therapy for borderline resectable pancreatic cancer. (21st November 2022)

17. Patient-derived orthotopic xenograft models of sarcoma. (28th January 2020)

18. Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models. (7th February 2019)

19. Pazopanib regresses a doxorubicin-resistant synovial sarcoma in a patient-derived orthotopic xenograft mouse model. (June 2019)